Forest Laboratories Inc

Forest Laboratories — Proxy Contest (July 2012)

170 slides from Forest Laboratories's proxy contest presentation, Jul 20, 2012

  1. Slide 1: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  2. Slide 2: Francis I. Perier, Jr.

    Francis I. Perier, Jr. Executive Vice President, Finance & Administration and Chief Financial Officer Forest Laboratories, Inc.

  3. Slide 3: Safe Harbor

    Safe Harbor Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA ap

  4. Slide 4: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  5. Slide 5: Howard Solomon

    Howard Solomon Chairman and Chief Executive Officer Forest Laboratories, Inc.

  6. Slide 6: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  7. Slide 7: Marco Taglietti, MD

    Marco Taglietti, MD President and Chief Medical Officer, Forest Research Institute, Inc. Senior Vice President, Research & Development, Forest Laboratories, Inc.

  8. Slide 8: Sustainable Growth Beyond 2012

    Sustainable Growth Beyond 2012 Forest Laboratories, Inc.

  9. Slide 9: Creating Sustainable Growth Beyond 2012

    Creating Sustainable Growth Beyond 2012 Our “Late Eight” strategy to replace Lexapro sales nebivolol Launch, Bystolic® milnacipran Launch, Savella® ceftaroline Launch, Teflaro® roflumilast Launch, Daliresp® aclidinium Under Review linaclotide Under Review levomilnacipran NDA in 2012 Cariprazine NDA

  10. Slide 10: Creating Sustainable Growth Beyond 2012

    Creating Sustainable Growth Beyond 2012 The “Next Nine” Viibryd strategy to replace Lexapro sales nebivolol Launch, Bystolic® milnacipran Launch, Savella® ceftaroline Launch, Teflaro® roflumilast Launch, Daliresp® aclidinium Under Review linaclotide Under Review levormilnacipran NDA in 2012 caripraz

  11. Slide 11: Strategy and Execution

    Strategy and Execution Product Selection • Science-based and market-relevance • Thoughtful and thorough due-diligence Product Development • Well defined target profile and product positioning • Efficient R&D Drug development to meet target profile Post-Marketing Support • Maximize value through scie

  12. Slide 12: R&D Facts and Figures

    R&D Facts and Figures • Over 1,500 people working in R&D - 1,100+ employees and 400+ contractors - 250+ MD/PhD/PharmDs • $850MM operating budget in FY2013 • Currently, 18 Products in R&D: - 4 in Phase I/II (8 Trials) - 8 in Phase III (14 Trials) - 6 in Phase IV (8 Trials, 7 Pediatric Trials) • Manag

  13. Slide 13: R&D Facts and Figures

    R&D Facts and Figures • Global R&D Organization - 22,000+ patients, in 2,100+ sites, in 49 trials, in 21 countries in FY2012 • In the last five years: - 7 NDA/sNDA filed in 9 indications, with 6 different FDA divisions - 6 approvals... soon to be 8

  14. Slide 14: R&D Facts and Figures

    R&D Facts and Figures • Support activities in FY2012 - Toxicology – 48 Studies - Pharmacology – 40 Studies - Clinical Pharmacology – 43 Studies - Health Economics – 49 Studies - Publications – 715 Publications

  15. Slide 15: Cardiovascular CNS Pain GI Respiratory Anti-Infectives

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda NamendaXR cariprazine levomilnacipran Savella GRT-6005 Linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

  16. Slide 16: Cardiovascular/Metabolic

    Cardiovascular/Metabolic • Maximize value of current products Bystolic Phase IV Support • 11 Phase IV Studies • +3,700 patients • Over 600 sites Life Cycle • FDC nebivolol/valsartan • Phase III ongoing • Filing in FY2014 • Expand pipeline - Azimilide (Antiarrhythmic in patients with ICD – Phase III)

  17. Slide 17: Submission Plan

    Submission Plan FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017 CY2009 CY2010 CY2011 CY2012 CY2013 CY2014 CY2015 CY2016 aclidinium NDA aclidinium/formoterol NDA azimilide NDA cariprazine NDA sNDA ceftaroline NDA Teflaro ceftaroline/avibactam NDA ceftazidime/avibactam NDA GRT6005 NDA levolmin

  18. Slide 18: Forest R&D Summary

    Forest R&D Summary • Outstanding track record in product selection, drug development and life-cycle management - A global R&D organization led by an experienced management team • Supporting the Present... - Extensive life-cycle and Phase IV programs to support currently marketed products • ...while

  19. Slide 19: Sustainable Growth Beyond 2012

    Sustainable Growth Beyond 2012 Forest Laboratories, Inc.

  20. Slide 20: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  21. Slide 21: Gavin Corcoran, MD

    Gavin Corcoran, MD Executive Vice President Research & Development, Early and Clinical Development Forest Research Institute, Inc.

  22. Slide 22: Therapeutic categories and products

    Cardiovascular Bystolic nebivolol/ valsartan azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran Pain Savella GRT-6005 GI linaclotide Respiratory Daliresp aclidinium aclidinium/ formoterol Anti-lnfectives Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

  23. Slide 23: Mood Disorders Psychosis

    Mood Disorders Psychosis Anxiety Depression Severe Depression Bipolar Depression Mania Schizophrenia Serotonin 5HT Norepinephrine Dopamine (SSRI & 5HT1a) Levomilnacipran (SNRI) Cariprazine (D2/D3 partial agonist)

  24. Slide 24: Viibryd (vilazodone)

    ViibrydTM (vilazadone) • SSRI with 5HT1a partial agonism • Indicated for MDD • Ongoing program to further define the utility of this drug for patients - Low dose - Relapse prevention - Pediatrics - General Anxiety Disorder

  25. Slide 25: Levomilnacipran Pharmacology

    Levomilnacipran Pharmacology • A new SNRI for the treatment of MDD - Greater selectivity for the NE transporter - More balanced increase in 5HT and NE in the brain • Relief of symptoms of depression • Potential for a positive effect on patient functionality

  26. Slide 26: Levomilnacipran

    Levomilnacipran Effect on Symptoms and Function • Three pivotal trials examining doses from 40-120mg/day - MADRS change from baseline - SDS change from baseline • Significant effect on both scores MD-01 MADRS LSMD (Placebo-Adjusted) -1 -2 -4 -5 -6 -7 * ** *** *P<0.05, **P<0.01, ***P<0.001 versus pla

  27. Slide 27: Levomilnacipran

    Levomilnacipran Effect on Symptoms and Function • Three pivotal trials examining doses from 40-120mg/day - MADRS change from baseline - SDS change from baseline • Significant effect on both scores • Dose response in study with all 3 doses (MD-01) • Lower rate of common adverse effects than most othe

  28. Slide 28: Cariprazine Pharmacology

    Cariprazine Pharmacology • Dopamine receptor partial agonist - D3 preferring, but partial agonist of D2 and D3 receptors - Less effect on histamine, adrenergic and 5HT2c • Suitable for the treatment of a range of conditions • Initial development for 2 indications - Schizophrenia and acute mania • 3

  29. Slide 29: Significant Effect in Schizophrenia

    Significant Effect in Schizophrenia Comparative Results for Schizophrenia (PANSS) Mean change from baseline RGH-MD-16 RGH-MD-04 RGH-MD-05 0 -5 Placebo -10 CAR 1.5 -15 CAR 3 -20 CAR 4.5 RIS 4 0 -5 Placebo -10 -15 CAR 3 -20 ARI 10 CAR 6 -25 -30 0 -5 Placebo -10 -15 CAR 3-6 CAR 6-9 -25 -30 0 1 2 3 4 5

  30. Slide 30: Significant Effect in Acute Mania

    Significant Effect in Acute Mania Comparative Results for Mania (YMRS) Mean change from baseline RGH-MD-31 RGH-MD-32 RGH-MD-33 0 -5 Placebo -10 CAR 3-12 -15 -20 0 -5 -10 Placebo -15 CAR 3-12 0 -5 Placebo -10 CAR 6-12 CAR 3-6 -20 0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 21 Improvement

  31. Slide 31: Favorable Adverse Event Profile

    Favorable Adverse Event Profile • Most common adverse effects - Insomnia, headache, constipation • Low potential for - Clinically relevant weight gain, somnolence and EPS/EPD • Few changes on metabolic parameters - Liver enzymes, blood lipids, prolactin, CPK • Akathisia - Up to 14% in schizophrenia

  32. Slide 32: Focus on Pain

    Focus on Pain • Savella - Indicated for the treatment of fibromyalgia • GRT6005 - Novel opioid for chronic pain - Potent activity through the mu and OLR-1 receptors - Currently in Phase II • Osteoarthritis, neuropathic pain, low back pain • Cancer pain (ex-US)

  33. Slide 33: Linaclotide

    Linaclotide • Ongoing unmet need - IBS-C - Chronic constipation • Conditions characterized by - Bowel symptoms • Constipation - Abdominal symptoms • Bloating, discomfort linaclotide Lumen Cl HCO3 Na H2O GC-C CFTR P GTP cGMP PKGII Serosa Afferent pain fibers

  34. Slide 34: Linaclotide Pivotal Data

    Linaclotide Pivotal Data • Phase III - 2 large studies in CC and 2 in IBS-c - 2 long term studies • Endpoints focused on demonstrating effect on bowel and abdominal symptoms - Significant effect on all primary and secondary parameters - Relief noted within a week of therapy

  35. Slide 35: Randomized Withdrawal

    Randomized Withdrawal CC Patients Stool Frequency (CSBM) CSBMs 0 1 2 3 Treatment Period RW Period BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Trial Week Treatment Period 290 µg Placebo IBS-C Patients Stool Frequency (CSBM) Treatment Period RW Period CSBMs 0 1 2 3 BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

  36. Slide 36: Linaclotide Phase III IBS-C Trial

    Linaclotide Phase III IBS-C Trial Weekly Change in Abdominal Symptoms Treatment Groups 266 µg Placebo Discomfort % Change 0 -10 -20 -30 -40 -50 -60 BL 2 4 6 8 10 12 14 16 18 20 22 24 26 Trial Week Bloating % Change 0 -10 -20 -30 -40 -50 -60 BL 2 4 6 8 10 12 14 16 18 20 22 24 26 Trial Week Fullness %

  37. Slide 37: Robust pipeline in three therapeutic areas

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781 • Robust

  38. Slide 38: Scientific programs beyond registration studies

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781 • Scienti

  39. Slide 39: Therapeutic focus of complementary medicines

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781 • Our the

  40. Slide 40: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  41. Slide 41: Harry J. Sacks, MD, FAAP

    Harry J. Sacks, MD, FAAP Executive Director, Clinical Development – Respiratory Forest Research Institute, Inc.

  42. Slide 42: Cardiovascular CNS Pain GI Respiratory Anti-Infectives

    Cardiovascular CNS Pain GI Respiratory Anti-lnfectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda NamendaXR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

  43. Slide 43: Improve Lives of Patients with Respiratory Diseases

    Improve lives of PATIENTS WITH RESPIRATORY DISEASES Forest Laboratories, Inc.

  44. Slide 44: Respiratory Overview

    Respiratory Overview Goal: Improve lives of patients with respiratory diseases • Robust COPD development programs underway • Product differentiation studies for all products • Investigate products in other respiratory conditions such as asthma • Seek out and invest in new treatments

  45. Slide 45: Managing the Spectrum of COPD

    Managing the Spectrum of COPD Forest Laboratories, Inc.

  46. Slide 46: Managing the Spectrum of COPD

    Managing the Spectrum of COPD • Affects as many as 24 million Americans1 • Third leading cause of death in US2 • Breathlessness is leading symptom aclidinium / formoterol aclidinium Daliresp MILD MODERATE SEVERE VERY SEVERE Source: 1 COPD Foundation Website: http://www.copdfoundation.org/COPDYOU/Abo

  47. Slide 47: Aclidinium Bromide: A Novel Anticholinergic Bronchodilator

    Aclidinium Bromide: A Novel Anticholinergic Bronchodilator Efficacy Improved lung function 24 hour control Symptom relief Safety Well tolerated Low drug interaction Successful FDA AdCom Inhaler Simple to use Patient friendly

  48. Slide 48: COPD Treatment Options

    COPD TREATMENT OPTIONS Forest Laboratories, Inc.

  49. Slide 49: Aclidinium Bromide: A Novel Anticholinergic Bronchodilator

    Aclidinium Bromide: A Novel Anticholinergic Bronchodilator 350 300 250 200 150 100 -50 -100 Evening administration Aclidinium 400 ug * BID (N=29) Tiotropium 18 ug QD (N=28) Placebo (N=30) 0 1 2 4 5 6 7 8 10 11 12 13 14 16 17 18 19 20 22 23 24 Time, h Study LAS-MD-23; presented at Feb. 23, 2012 FDA A

  50. Slide 50: Further Studies Planned

    Further Studies Planned Forest Laboratories, Inc.

  51. Slide 51: Further Studies Planned

    Further Studies Planned • Relative effect of aclidinium over 24 hours - Direct comparison to approved product • Exacerbations - Confirm aclidinium reduces flare ups • Exercise Tolerance - Confirm aclidinium enables patients to better tolerate physical exertion

  52. Slide 52: Aclidinium + Formoterol FDC

    Aclidinium + Formoterol FDC Forest Laboratories, Inc.

  53. Slide 53: Aclidinium + Formoterol FDC

    Aclidinium + Formoterol FDC • Phase III pivotal studies currently enrolling • For moderate to severe patients requiring more symptom control than with a single agent - Step between monotherapy and inhaled steroids - May delay need for steroids • Established efficacy in Phase II; well tolerated • NDA

  54. Slide 54: Importance of Reducing COPD Exacerbations

    Importance of Reducing COPD Exacerbations • History of exacerbations predicts higher likelihood of future exacerbations • Reduction of exacerbations is a key component of COPD management1 • Exacerbations are associated with accelerated deterioration in lung function and increased risk of death • Dal

  55. Slide 55: Daliresp (roflumilast)

    Daliresp (roflumilast, 500 mcg tablets) Severe and Very Severe COPD “DALIRESP is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations” • Approved February 2011 - Once daily oral treatment - Fi

  56. Slide 56: Cardiovascular CNS Pain GI Respiratory Anti-Infectives

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Namenda NamendaXR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

  57. Slide 57: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  58. Slide 58: Paul C. Grint, MD

    Paul C. Grint, MD President, Cerexa, Inc.

  59. Slide 59: Cardiovascular CNS Pain GI Respiratory Anti-Infectives

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

  60. Slide 60: Bad Bugs Need Drugs

    Bad Bugs Need Drugs • Antibiotic resistant infections in the US - 8 million hospital days - $20B annual cost Public health threat • National security threat • The 10 x '20 Initiative • NewDrugs4BadBugs - European initiative against antimicrobial resistance • GAIN Legislation - Generate Antibiotic In

  61. Slide 61: Bad Bugs Need Drugs

    Bad Bugs Need Drugs 10x ‘20 Ten new ANTIBIOTICS by 2020 1 ceftaroline fosamil: Forest Laboratories, Inc. Approved October 29, 2010 We could potentially deliver an additional 2 to 3 of these 10

  62. Slide 62: Spectrum of Activity

    Spectrum of Activity Resistant Gram+ Gram+ Gram– Resistant Gram– Teflaro ceftaroline + avibactam ceftazidime + avibactam MRSA MDRSP S. pneumoniae S. aureus H. influenzae E. coli K. pneumoniae ESBL producing Gram– P. aeruginosa Nabriva BC-3781

  63. Slide 63: Ceftaroline Life Cycle Studies

    Ceftaroline Life Cycle Studies patch® pediatric antibiotic therapy with ceftaroline in the hospital • Pediatric PK studies including premature newborns • Comparative studies in children - Community acquired bacterial pneumonia - Complicated skin infections - CABP at risk of MRSA • Study designs for

  64. Slide 64: AWARE: Assessing Worldwide Antimicrobial Resistance Evaluation

    AWARE: Assessing Worldwide Antimicrobial Resistance Evaluation • In Vitro US Surveillance Program • No trend of reduced susceptibility to ceftaroline for pathogens tested between 2008 and 2011 • Expanding program - 70 centers in 2011 - 200 centers in 2012 % Susceptible to ceftaroline (FDA Breakpoint

  65. Slide 65: Important Utility of ß-Lactam Antibiotics

    Important Utility of ß-Lactam Antibiotics • ß-Lactams have been effective life saving antibiotics for five decades • ß-lactamases are threatening the utility of ß-Lactams - ß-Lactamase-induced resistance is increasing worldwide - No treatment available for new extended ß-lactamases - Carbepenems are

  66. Slide 66: Avibactam: Next Generation ß-Lactamase Inhibitor

    Avibactam: Next Generation ß-Lactamase Inhibitor • Non ß-lactam ß-lactamase inhibitor - Does not bind to PBPs - No intrinsic antibacterial activity • Inhibits a broad spectrum of clinically important ß-lactamases - Older inhibitors do not offer coverage of important enzymes such as KPC or AmpC • Doe

  67. Slide 67: Avibactam Combinations

    Avibactam Combinations Globally, over a million patients a year suffer from infections known or suspected to be resistant to cephalosporins, and is expected to grow by more than 25% over the next decade • Ceftazidime Avibactam - Phase III program to treat serious Gram-negative bacterial infections h

  68. Slide 68: BC-3781 Nabriva Therapeutics

    BC-3781 Nabriva Therapeutics • Novel class of antibiotics, the pleuromutilins - Active against a wide range of Gram-positive pathogens as well as certain Gram-negative organisms • No cross resistance • Low propensity for inducing resistance itself • Developed both intravenous and oral forms to treat

  69. Slide 69: Summary

    Summary • Very significant antibiotic portfolio that covers a wide spectrum of Gram-positive and Gram-negative pathogens • Urgent medical need for new antibiotic development • Potential to deliver an additional 2 to 3 antibiotics for the IDSA 10 x ‘20 Initiative Bad Bugs Need Drugs 10x ‘20 Ten new A

  70. Slide 70: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  71. Slide 71: David F. Solomon

    David F. Solomon Senior Vice President, Corporate Development & Strategic Planning Forest Laboratories, Inc.

  72. Slide 72: Forest Objective

    Forest Objective Forest Laboratories, Inc.

  73. Slide 73: Forest Objective

    Forest Objective We will achieve long-term growth by maintaining our simple but powerful strategy License or acquire new products Rigorous scientific development Effective marketing and sales Vigorous protection of our intellectual property

  74. Slide 74: Forest Objective

    Forest Objective We will enhance long-term growth by extending that strategy Life cycle programs New therapeutic areas Earlier stage programs Larger or more difficult to manufacture molecules Adjacent business opportunities Expansion outside the United States

  75. Slide 75: Forest Business Development

    Forest Business Development Opportunistic Targeted Engineered Unsolicited Partnering Meetings Wall Street & Venture Capital Company Focus Therapeutic Franchise & Mechanism Focus Medical Meetings Companies Looking

  76. Slide 76: Scope of Business Development Activity

    Scope of Business Development Activity 350-450 Screened by Business Development 100-150 Reviewed Internally 15-25 Due Diligence 2-6 Transactions

  77. Slide 77: Partner-Oriented Business Development: Partnerships and Acquisitions Since 2004

    Partner-Oriented Business Development 25 Product Partnerships And Acquisitions Since 2004

  78. Slide 78: Partner-Oriented Business Development

    Partner-Oriented Business Development Marketed / Next 9 Product Partnerships

  79. Slide 79: Forest is a Partner of Choice

    Forest is a Partner of Choice Reputation for treating partners fairly and with respect Large enough to compete with the major pharma companies and small enough to focus on each product History of success developing and launching in-licensed products Senior level engagement across the partnership Qui

  80. Slide 80: Continued Success of Forest's Partner-Oriented Strategy

    Continued Success of Forest’s Partner-Oriented Strategy Numerous repeat collaborations with our partners Many novel and interesting product opportunities available

  81. Slide 81: Forest is Growing its Global Footprint

    Forest is Growing its Global Footprint Forest will expand where opportunities exist In 3 years, we have grown from operating in 3 countries to 10 countries Established in Canada Expanding in Europe Interest in emerging markets

  82. Slide 82: Forest Canada

    Forest Canada Forest Canada fully established Canadian rights to most of the “Next Nine” products NDS for Bystolic under review by Health Canada Launch projected early CY’13 NDS for Viibryd and linaclotide to be filed later this year, and NDS for levomilnacipran and cariprazine to be filed during CY

  83. Slide 83: Forest Europe

    Forest Europe Tosara and Forest UK (OTC Business) — Sales of ~$80M Key products are Sudacrem and Infacol Sold directly in UK and Ireland, and exported to over 35 countries

  84. Slide 84: Forest Europe

    Forest Europe Pharma Business — Sales of ~$50M Largest product is Colistin Nebulized antibiotic for prevention of respiratory infections in cystic fibrosis patients In 2011 acquired rights to Colistin in several Central EU countries Established affiliates in Germany, Austria, Netherlands, Belgium &

  85. Slide 85: Forest Europe

    Forest Europe Pharma Business — Sales of ~$50M Approval for Colobreathe in January 2012 Dry powder inhaler of the same antibiotic Will establish affiliates in all major EU countries, Scandanavia and high value Eastern EU markets Launch in Ireland, Germany, Austria, Netherlands & Denmark CY’13; addit

  86. Slide 86: Forest Will Build Strategically in International Markets

    Forest Will Build Strategically in International Markets International business must be structured to support long-term, sustainable, profitable growth Need to be sensitive to regional differences Business development to be globally deployed and looking for global and regional product rights Interna

  87. Slide 87: Building Long-Term Growth

    Building Long-Term Growth Forest has the right strategy, based on licensing and acquiring interesting products Forest will continue to build our therapeutic franchises and will be opportunistic in looking at new product and novel business opportunities Forest will expand our strategy globally

  88. Slide 88: The Right Strategy for Today and for the Future

    The Right Strategy for Today and for the Future

  89. Slide 89: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  90. Slide 90: Elaine Hochberg

    Elaine Hochberg Executive Vice President, Sales & Marketing and Chief Commercial Officer Forest Laboratories, Inc.

  91. Slide 91: A Focus On Our Commercial Philosophy & Therapeutic Areas

    A Focus On Our Commercial Philosophy & Therapeutic Areas Forest Laboratories, Inc.

  92. Slide 92: Forest's Rich Commercial History

    Forest’s Rich Commercial History Past 15 Years • Total revenue from $300MM to $4B • 14 launches - 14 products - 17 indications Significant Product Launches Celexa citalopram HBr Benicar TABLETS Lexapro Bystolic Namenda “The Forest Way” Ability to right-size and deploy commercial effort to create val

  93. Slide 93: Commercial Operations

    Commercial Operations Forest Laboratories, Inc.

  94. Slide 94: Commercial Operations 2012

    Commercial Operations 2012 ELAINE HOCHBERG Executive Vice President & Chief Commercial Officer Global Commercial & U.S. Marketing Office Based Sales Managed Markets, Government & Policy Product Management Global Commercialization Marketing Services Digital Marketing & Marketing Communications 4 Prim

  95. Slide 95: Forest's Advantage: Field Force Strength

    Forest’s Advantage: Field Force Strength RANKED 1st on Selling Power magazine’s “50 Best Companies to Sell For” in 20111 We Target per Year: • ~ 250,000 physicians • ~ 3,000 hospitals and clinics • ~ 500 senior care pharmacies Productivity2 1st Forest 2nd AstraZeneca 3rd Pfizer 4th Takeda 5th Novart

  96. Slide 96: Primary Care

    Primary Care Forest Laboratories, Inc.

  97. Slide 97: Forest Reps Consistently Reach More Than 80% of Primary Care Physicians

    Forest Reps Consistently Reach More Than 80% of Primary Care Physicians* More Than Twice Per Month Reach 90% 85% 80% 75% 70% 65% 60% Reach and Frequency to 98,000 Decile 3–10 PCP’s Reach Call Frequency 81.2% 82.5% 81.8% 83.7% 2.55 2.55 2.65 2.78 2008 2009 2010 2011 3.2 3.1 2.9 2.8 2.7 2.5 2.4 2.3 2.

  98. Slide 98: Forest Position with PCPs is Strong and Growing Stronger

    Forest Position with PCPs is Strong and Growing Stronger Company Details – Primary Care Physicians Details (thousands) 5,000 4,000 3,000 2,000 1,000 CY2007 CY2008 CY2009 Forest Merck AstraZeneca Lilly Novartis Takeda Abbott Sanofi Aventis CY2010 Pfizer GSK Boehringer CY2011 Source: IMS IPS, Office-b

  99. Slide 99: Commercial Philosophy

    Commercial Philosophy Forest Laboratories, Inc.

  100. Slide 100: Forest's Commercial Philosophy

    Forest’s Commercial Philosophy • Primarily Primary Care-Centric (with appropriate specialty overlays) • Therapeutically Agnostic • Differentiated Products • Professionally Driven • Sensibly Priced • Diversifying “Geographically”

  101. Slide 101: Primary Care Professionals Generate >65% of TRx's

    Primary Care Professionals Generate >65% of TRx’s % of TRx Decile 3-10 MDs Anti-Depressants (SRI) Beta Blockers COPD Primary Care Professionals (Includes NPs & PAs) 69% 73% 71% Specialists 23% 22% 21% Others 8% 5% 8% Total 100% 100% 100% IMS Xponent 12 months, Ending April 2012

  102. Slide 102: Greater Than One-half of Naïve and New to Brand Patients Treated by Primary Care

    Greater Than One-half of Naïve and New to Brand Patients are Treated by Primary care Physicians Percent of Patients Treated by PCPs Naïve to Market New to Brand 100% 80% 60% 40% 20% 0% 68% 64% 56% 54% 60% 60% 62% 61% HTN Depression Alzheimer COPD Source: IMS Custom Patient Study, 2012

  103. Slide 103: Forest Competes in Major Primary Care Markets

    Forest Competes in Major Primary Care Markets Ranking of Therapeutic Classes Based on Primary Care TRx Volume Total Prescriptions (000) 500,000 450,000 400,000 350,000 300,000 250,000 200,000 150,000 100,000 50,000 Cardiovascular Psychotherapeutics Antihyperlipidemic Analgesics Diabetes Anti-Infecti

  104. Slide 104: Success with Products

    SUCCESS WITH PRODUCTS Forest Laboratories, Inc.

  105. Slide 105: Bystolic A Case Study

    Bystolic A Case Study TRx (Absolute Numbers) Bystolic Prilosec Januvia Symbicort Vyvanse Bexilant Pradaxa Janumet 3,000,000 2,250,000 1,500,000 750,000 Bystolic 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Quarters Source: IMS, NPA, May 12 Note: Dexilant was originally marketed as Kapldex

  106. Slide 106: PCP Response to Bystolic Detailing: Launches Take Two Years

    PCP Response to Bystolic Detailing: Launches Take Two Years Bystolic TRx per MD 0 6 12 18 24 30 36 42 Bystolic Calls per MD Source: Internal Data, 75,970 physicians were analyzed Rx Data- IMS Xponant Year 2 Year 1

  107. Slide 107: Strong Growth Performance in 4th Year with Broad Managed Care Coverage

    Strong Growth Performance for in its’ 4th Year with Broad Coverage by Managed Care % Unrestricted T2/T3 Access Bystolic TRx 100% 80% 60% 40% 20% 0% 73% 82% 83% 84% 1,600 1,400 1,200 1,000 Total Rx (000) 1Q 08 2Q 08 3Q 08 4Q 08 1Q 09 2Q 09 3Q 09 4Q 09 1Q 10 2Q 10 3Q 10 4Q 10 1Q 11 2Q 11 3Q 11 4Q 11 1

  108. Slide 108: Forest Pipeline

    Forest Pipeline FY2013 aclidinium (COPD) linaclotide (CC/IBSc) FY2014 Namenda XR (Alzheimer’s Disease) levomilnacipran (MDD) cariprazine (schizophrenia and mania) FY15 and Beyond Bystolic / valsartan (Hypertension) aclidinium / formoterol (COPD) Viibryd (GAD) cariprazine (Depression & Bipolar Disord

  109. Slide 109: Sales Rep High Driver of MD Adoption

    Sales Rep High Driver of MD Adoption Stated and Implied Importance in Making a Prescribing Decision at Launch for Physicians DTC Advertising Sales Reps Samples Perceived Unmet Need Coverage Out-of-Pocket Cost Pre-launch Awareness Guidelines at Launch Novel MOA Expert Advocacy Dosing Manufacturer Cre

  110. Slide 110: What Do Doctors Really Want?

    What Do Doctors Really Want? “Practical” Help, Survey Finds Doctors also see a greater practical benefit in meeting with sales reps… “who are trained beyond their own product, and prepared for a serious discussion of multiple therapeutic options”. Source: “What Physicians Want” Survey by Public’s To

  111. Slide 111: Forest's Value is in the Mix

    Forest’s Value is in the Mix Industry PCP Total Prescriptions by Therapeutic Area Anti-Infectives 5% Respiratory 5% GI 5% Pain 7% CNS 11% Other 39% Cardiovascular 28% Forest Product Line Cardiovascular (3) Bystolic nebivolol/valsartan azimilide CNS (4) Viibryd Namenda/Namenda XR Cariprazine Levomiln

  112. Slide 112: Significant Overlap Among PCPs in Different Therapeutic Areas

    Significant Overlap Among PCPs in Different Therapeutic Areas SSRI 55% 3 Products 80% 2 Products 87% linaclotide COPD Beta blocker IMS Xponent 12 months, Ending April 2012

  113. Slide 113: Forest - Diversifying Geographically

    Forest - Diversifying “Geographically” Ex – US Canada Europe Latin America other US – Institutions Anti-infectives Respiratory Alzheimer’s Other

  114. Slide 114: Average Uptake for Hospital INJ Antibiotics

    Average Uptake for Hospital INJ Antibiotics: Slower Ramp and Longer Period Avg Retail Uptake Avg Hospital INJ Antibiotics Uptake Percent of Peak Volume 0% 25% 50% 75% 100% Months Post-Launch M1 M12 M23 M34 M45 M56 M67 M78 M89 M100 Source: IMS NPA Prescriptions IMS National Sales Perspectives

  115. Slide 115: Forest's Commercial Philosophy

    Forest’s Commercial Philosophy Look for efficiencies to build long term value Forest Laboratories, Inc.

  116. Slide 116: Building the Future

    Building the Future A Focus On Our Products & Therapeutic Categories Forest Laboratories, Inc.

  117. Slide 117: William Meury

    William Meury Senior Vice President, Global Commercial & US Marketing Forest Laboratories, Inc.

  118. Slide 118: Building the Future

    Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.

  119. Slide 119: Cardiovascular

    Cardiovascular Bystolic nebivolol/ valsartan Azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran pain Savella GRT-6005 GI linaclotide Respiratory Daliresp aclidinium aclidinium/ formoterol Anti-Infectives Teflaro ceftaroline/avibactam ceftazidime/avibactam BC3781

  120. Slide 120: User Trends and Prescriptions Are Strong

    User Trends and Prescriptions Are Strong Cumulative Bystolic Prescribers 300,000 225,000 150,000, 75,000, 264,057 1/4/08 10/9/09 6/13/08 11/21/08 5/1/09 3/19/10 8/27/10 2/4/11 7/15/11 12/23/11 5/25/12 Over 5 Million Prescriptions Prescriptions up 20% in 1st calendar quarter vs. prior year 550 530 51

  121. Slide 121: Market for 1st/2nd Line is Larger

    Market for 1st /2nd Line is Larger Patients receiving 3 or 4 anti-hypertensives of control BP Position Bystolic Here! 26% 74% Patients received 1 or 2 anti-hypertensives to control BP Sources: Decision Resources (Pharamacor 2009); IMS/SDI (Custom) Hypertension Monthly Report, January 2012.

  122. Slide 122: Bystolic is Being Used 1st or 2nd Line

    Bystolic is Being Used 1st or 2nd Line Bystolic Line of Therapy Difference in 1st and 2nd Line 4th Line 15% 3rd Line 27% 1st & 2nd Line 58% Bystolic 4% -1% 5% 4% 3% 2% 0% (1%) (2%) Beta Blocker Market Source: IMS Study Drug Order as Written, First Filled

  123. Slide 123: Bystolic Clinical Studies

    11 Bystolic Clinical Studies Over 4 Years Study Conclusion Weiss/Greathouse Lacourciere Weiss Neutel Lacourciere Weber Saunders Punzi Registration Registration Lukic Monotherapy Monotherapy Monotherapy Stage 2 Add on to ACE, ARB, HCTZ Initial combination with ACE Black patients Hispanic patients You

  124. Slide 124: Cardiovascular

    Cardiovascular Bystolic nebivolo valsartan azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran Pain Savella GRT-6005 GI linaclotied Respiratory Daliresp aclidinium aclidinium/formoterol Anti-Infectives Teflaro ceftaroline/ avibactam ceftazidime/avibactam BC3781

  125. Slide 125: Bystolic + valsartan

    Bystolic + valsartan 54.2MM Prescriptions ARB + BB ARB + BB + HCT ARB + HCT 10MM Rx 15.9MM Rx 28.3MM Rx $3.3B Annual Sales

  126. Slide 126: Cardiovascular

    Cardiovascular Bystolic nebivolol/valsartan azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran Pain Savella GRT-6005 GI Linclotide Respiratory Daliresp Aclidinium Aclidinium/formoterol Anti-Infectives Teflaro Ceftaroline/avibactam Ceftazidime/avibactam BC3781

  127. Slide 127: Namenda

    Namenda Large User Base 173,000 129,750 86,500 43,250 173,000 MD Users High Satisfaction Rate 7.0 6.0 5.0 4.0 3.0 2.0 1.0 5.1 5.1 5.0 Basic ADLs Cognitive Decline Quality of Life Source: IMS XPO & Market Research

  128. Slide 128: Once-Daily Namenda XR

    Once-Daily NamendaXR (memantine HCL) extended release capsules TM

  129. Slide 129: Once-Daily Namenda XR

    Once-Daliy Namenda XR (Memantine HCI)extended release capsules Demonstrated effective with all ACHEI Improvement in cognition, function, and behavior AE consistent with Namenda Once a day high dose formulation TM

  130. Slide 130: Viibryd is off to a Strong Start

    Viibryd is off to a Strong Start Prescriptions Market Share % 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 TM May-12 Total Prescription Volume (000s) TRx Mkt Share Overall volume up 20% since start of 2012 Source: IMS NGPS NPA, May 2012

  131. Slide 131: Viibryd Prescribers are on the Rise

    Viibryd Prescribers are on the Rise Prescribers Since Launch Prescribers Since Launch 60,000 45,000 30,000 15,000 0 6/17/11 7/29/11 9/9/11 10/21/11 12/2/11 1/13/12 2/24/12 4/6/12 5/18/12 1,000 added/week 50,516 Source: IMS Xponent, Week ending 5/18/2012

  132. Slide 132: Viibryd is off to a Strong Start

    Viibryd is off to a Strong Start Physician Reported Use of Viibryd 4+ Line 17% 3rd Line 28% 1st Line 29% 2nd Line 26% Source: Market Research TM

  133. Slide 133: Viibryd

    Viibryd TM

  134. Slide 134: Levomilnacipran

    LEVOMILNACIPRAN Forest Laboratories, Inc.

  135. Slide 135: Levomilnacipran

    Levomilnacipran Dual Reuptake Inhibitor for Major Depressive Disorder (MDD) 200 million prescriptions written Sales for antidepressants approximately $18B Only 30–40% of patients on any achieve remission Source: STAR-D and GYK, 2008

  136. Slide 136: Levomilnacipran

    Levomilnacipran Dual Reuptake Inhibitor for Major Depression Disorder (MDD) Strong effect on the MADRAS Significant effect on function Acceptable adverse event profile Source: STAR D and GIK, 2008

  137. Slide 137: Market Positions for Levomilnacipran

    Market Positions for Levomilnacipran 1st line 2nd line 3rd line Treatment Resistant SSRIs SNRIs Wellbutrin Anti-psychotics Viibryd levomilnacipram

  138. Slide 138: Cariprazine

    CARIPARAZINE Forest Laboratories, Inc.

  139. Slide 139: Cariprazine: A Novel Next Step

    Cariprazine: A Novel Next Step D2/5HT Antagonists D2 Partial Agonist New D3/D2 Partial Agonist Risperdal Zyprexa Seroquel Geodon Clozaril Invega Saphris Fanapt Latuda Abilify Cariprazine

  140. Slide 140: Recent Launch Performance

    Recent Launch Performance Total Rx (000s) Latuda #10 Saphris #8 Fanapt #9 M1 M3 M5 M7 M9 M11 M13 M15 M17 M19 M21 M23 Source: IMS NPA TRx, March 2012

  141. Slide 141: Bipolar Depression and MDD Markets

    Bipolar Depression and MDD Markets Abilify – $5.3B 22% 26% 39% 13% Source: IMS NSP, MAT April 2012; NDTI, MAT April 2012 Note: “Others” includes Psychoses unspecified, autism, anxiety, OCD, domestic Schizophrenia Bipolar Disorder Depression Others Seroquel/XR – $5.5B 29% 17% 41% 14%

  142. Slide 142: Cardiovascular CNS Pain GI Respiratory Anti-Infectives

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

  143. Slide 143: Current Treatments

    CURRENT TREATMENTS Forest Laboratories, Inc.

  144. Slide 144: Linaclotide Provides Multi-symptom Relief

    Linaclotide Provides Multi-symptom Relief Linaclotide addresses constellation of symptoms in CC/IBSc Relieve pain Relieve bloating and discomfort Improve bowel function

  145. Slide 145: Two Important Sources of Business

    Two Important Sources of Business Convert Rx and OTC markets Prescription Market 24% $2.2B $7.0B 76% OTC Market (@ branded RX pricing) Source: Market Research & IMS

  146. Slide 146: Linaclotide for CC and IBSc

    Linaclotide for CC and IBSc (MM) CC IBS-C Total Prevalence 26.0 13.2 39.2 Patients Seeking Care 7.9 7.6 15.5 Dissatisfied Patients (62-68%) 4.9 5.2 10.1 Satisfaction with current therapies is low 60-70% of patients seeking care are dissatisfied with current therapy Lieborman Study, 2010

  147. Slide 147: OTC Conversion Rates

    OTC Conversion Rates 40% 30% 20% 10% 0% 20% NSAIDs to Cox-2s 23% H2s to PPls 37% Sedating to Non-Sedating Antihistamines Source: Kline OTC Sales Date

  148. Slide 148: Linaclotide Post-launch

    Linaclotide Post-launch Promotional Effort - +1,500 representatives - 90,000 physicians Major educational campaign directed to patients

  149. Slide 149: Cardiovascular

    Cardiovascular Bystolic Nebivolol/ Valsartan Azimilide TTP-399 CNS Viibryd Namenda Namenda XR Cariprazine Levomilnacipran Pain Savella GRT-6005 GI Linaclotide Respiratory Daliresp Aclidinium Aclidinium/ Formoterol Anti-infectives Teflaro Ceftaroline/ Avibactam Ceftazidime/ Avibactam BC3781

  150. Slide 150: COPD Product Line

    COPD Product Line Aclildinium LAMA Acilidinium /formoterol LAMA/LABA Daliresp PDEIV Inhibitor Efficacy Moderate COPD Severe COPD

  151. Slide 151: Need for New Therapies

    Need for New Therapies Patients are Still Experiencing Symptoms Despite Treatment Overall PUD PCP 70% 53% 35% 18% 0% 55% 64% 46% 41% 52% 28% Experiencing symptoms with monotherapy Experiencing symptoms with combination Spiriva + ICS/LABA Source: Forest Physician COPD Research GfK COPD Study, 2008 Pe

  152. Slide 152: Daliresp off to a Strong Start with Pulmonologists

    Daliresp off to a Strong Start with Pulmonologists Overall volume up 42% since start of 2012 7,000 6,000 5,000 4,000 3,000 2,000 1,000 PUD Share 2.6% 2.1% 1.6% 1.1% 0.6% 0.1%-0.4% PUD Market Share TRx 0 5/27/11 7/8/11 8/19/11 9/30/11 11/11/11 12/23/11 2/3/2012 3/16/12 4/27/12 Updated Weekly Data Wee

  153. Slide 153: Daliresp off to a Strong Start

    Daliresp off to a Strong Start With Pulmonologists Total PUD Users 5,000 3,750 2,500 1,250 504 1,070 1,580 1,990 2,369 2,715 3,033 3,306 3,577 3,811 4,031 Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Source: IMS Xponent, Week ending 5/25/2012

  154. Slide 154: PCP Development

    PCP DEVELOPMENT Forest Laboratories, Inc.

  155. Slide 155: PCP Usage Doubles: 20,000 to 40,000

    PCP USAGE DOUBLES: 20,000 TO 40,000 Forest Laboratories,Inc.

  156. Slide 156: 44% Increase in Hospital Using Daliresp

    44% Increase in Hospital Using Daliresp Hospitals Purchasing 1,800 1,575 1,350 1,125 1,198 +531 Hospitals 1,729 Before Hospital Launch After Hospital Launch Updated Weekly Data Week Ending May 11

  157. Slide 157: Aclidinium

    ACLIDINIUM Forest Laboratories, Inc.

  158. Slide 158: Aclidinium

    Aclidinium Long acting inhaled anti-cholinergic bronchodilator Long residence time at M3 receptors and shorter residence time at the M2 receptors Novel, multi-dose device, Genuair Rapid effect on FEV1 Low incidence of side effects Novel, easy to use inhaler

  159. Slide 159: Aclidinium Promotional Effort

    Aclidinium Promotional Effort 1,500 representatives 90,000 physicians Sampling Advertising Peer to peer promotional programs

  160. Slide 160: Aclidinium-Formoterol

    ACLIDINIUM-FORMOTEROL Forest Laboratories, Inc.

  161. Slide 161: Cardiovascular

    Cardiovascular Bystolic Nebivolol/ Valsartan Azimilide TTP-399 CNS Viibryd Namenda Namenda XR Cariprazine levomilnacipran Pain Savella GRT-6005 GI Linaclotide Respiratory Daliresp aclidinium aclidinium/ formoterol Anti-infectives Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

  162. Slide 162: Teflaro

    Teflaro Purchasing Hospitals Above Cubicin Tygacil Zyvox TEFLARO Doribax Cubicin Vibativ Weekly Accounts Purchasing 1,500 1,125 W1 W6 W11 W16 W21 W26 W31 W36 W41 W46 W51 W56 W61 W66 W71 Weeks Post-Launch IMS, Hospital Report, 2012

  163. Slide 163: Teflaro

    Teflaro 20,000 15,000 10,000 5,000 Weekly DOT Days of Therapy Above to Zyvox W1 W6 W11 W16 W21 W26 W31 W36 W41 W46 W51 W56 W61 W66 W71 Tygacil Cubicin Doribax TEFLARO Zyvox Vibativ Weeks post-Launch Ims, Hospital Report, 2012

  164. Slide 164: Teflaro Has Demonstrated High Efficacy Rates in CABP & ABSSSI

    Teflaro Has Demonstrated High Efficacy Rates in CABP & ABSSSI Day 4 CABP TEFLARO 69.5% CABP Ceftriaxone 59.4% 0% 20% 40% 60% 80% 100% S. pneumoniae 100% 80% 60% 40% 20% 0% 85.7% 69.5% TEFLARO Ceftriaxone Day 3 ABSSSI TEFLARO 74.0% ABSSSI Vanco/Aztreonam 66.2% 0% 20% 40% 60% 80% 100% MRSA 100% 80% 60

  165. Slide 165: Usage Patterns

    Usage Patterns 40% 25% 30% 33% 20% 10% 0% Percentage of 1st line Use Emergency Department Use 100% 88% 75% 50% 25% 0% Satisfaction Source: Market Research

  166. Slide 166: Teflaro Prescribing Intentions are High

    Teflaro Prescribing Intentions are High Future Prescribing Expectation IDs and Internists 100% 2% 5% 75% 50% 98% 95% 25% 0% Plan to initiate use of Teflaro for cSSSI (n=43) Plan to initiate use of Teflaro for CABP (n=43) Source: Market Research

  167. Slide 167: Forest Antibiotic Franchise

    Forest Antibiotic Franchise First Line – Empiric Therapy Teflaro ceftaroline/avibactam ceftazidime/avibactam “Workhorse antibiotic” for cSSSI and CAP Ceftaroline with ESBL Coverage will expand use of ceftaroline for more severe infections Excellent activity against Gram- pathogens such as pseudomona

  168. Slide 168: Gram-negative U.S. Market Share

    Gram-negative U.S. Market Share Days of Therapy (non-retail) Carbapenems 14% Cephalosporins 13% IV Quinolones 34% Piperacillin/tazobactam 39% IV Quinolones Piperacillin/tazobactam Cephalosporins Carbapenems Data Source: IMS NSP Non-retail grams (MAT April 2012) converted to days of therapy using AMR

  169. Slide 169: Cardiovascular CNS Pain GI Respiratory Anti-Infectives

    Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 Linaclotide Daliresp aclidinium aclidinium/formoterol Teflaro ceftaroline/avibactam ceftazidime/avibactam BC3781

  170. Slide 170: Building the Future

    Building the Future A Focus on Our Products &Therapeutic Categories Forest Laboratories, Inc.

Forest Laboratories — Proxy Contest (July 2012) on 6ix